Eigen Therapeutics, founded in 2021, is a pioneering biotechnology company based in the United States. With the slogan "We help targeted therapies hit their mark," the company is on a mission to enhance cancer treatment by developing "priming" therapies. These therapies aim to address cancer heterogeneity by making cancer cells more susceptible to targeted treatments while bolstering the resilience of healthy cells.
The company's innovative approach involves a proprietary high-throughput discovery platform that merges biology and engineering. This platform integrates machine learning algorithms with robotic systems and custom laboratory software to discover new drug classes and potential therapies, ultimately aiming to save more lives.
Following a recent Seed Round investment on March 11, 2024, led by ZAKA VC, Eigen Therapeutics is well-positioned to advance its research and expand its impact in the biotechnology and life sciences sectors.